Theramex has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS(R) (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS(R) on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.